Sibrotuzumab

From WikiMD.org
Jump to navigation Jump to search

Sibrotuzumab

Sibrotuzumab (pronunciation: si-bro-tu-zu-mab) is a monoclonal antibody designed for the treatment of certain types of cancer. It was developed by Boehringer Ingelheim, a German pharmaceutical company.

Etymology

The name "Sibrotuzumab" is derived from the International Nonproprietary Names (INN), where "si-" refers to its source (S. cerevisiae), "bro-" refers to its target (brother of Regulator of Imprinted Sites), "tu-" indicates its tumor specificity, and "-mab" is a common suffix for monoclonal antibodies.

Mechanism of Action

Sibrotuzumab works by binding to the Fibroblast Activation Protein (FAP), a protein that is overexpressed in many types of tumors. By binding to FAP, Sibrotuzumab inhibits the growth and proliferation of cancer cells.

Clinical Trials

Sibrotuzumab has been tested in several clinical trials for its efficacy in treating various types of cancer, including colorectal cancer and lung cancer. However, as of now, it has not been approved for use by any major regulatory authority.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski